Aileron Therapeutics, Inc. – NASDAQ:ALRN
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 19 minutes
Aileron Therapeutics stock price monthly change
-29.87%
month
Aileron Therapeutics stock price quarterly change
-29.87%
quarter
Aileron Therapeutics stock price yearly change
-31.80%
year
Aileron Therapeutics key metrics
Market Cap | 37.98M |
Enterprise value | 945.29K |
P/E | -0.21 |
EV/Sales | N/A |
EV/EBITDA | -0.03 |
Price/Sales | N/A |
Price/Book | 0.32 |
PEG ratio | 0.05 |
EPS | -3.19 |
Revenue | N/A |
EBITDA | -18.57M |
Income | -18.06M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAileron Therapeutics stock price history
Aileron Therapeutics stock forecast
Aileron Therapeutics financial statements
| Jun 2023 | 0 | -1.78M | |
|---|---|---|---|
| Sep 2023 | 0 | -1.82M | |
| Dec 2023 | 134K | -7.33M | -5476.87% |
| Mar 2024 | 0 | -7.11M |
| 2027 | 127.66M | -4.82M | -3.78% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-03-20 | -0.77642 | -1.02 |
|---|
| Jun 2023 | 13991000 | 1.19M | 8.56% |
|---|---|---|---|
| Sep 2023 | 12822000 | 1.62M | 12.67% |
| Dec 2023 | 119286000 | 112.39M | 94.23% |
| Mar 2024 | 99192000 | 7.85M | 7.92% |
| Jun 2023 | -3.11M | 8.5M | 0 |
|---|---|---|---|
| Sep 2023 | -1.64M | 542K | -33K |
| Dec 2023 | -10.39M | -96K | 15.79M |
| Mar 2024 | -5.27M | 0 | 0 |
Aileron Therapeutics alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 15 |
| Jun 2024 | 15 |
| Jul 2024 | 15 |
Aileron Therapeutics other data
2.31%
-27.56%
of ALRN is owned by hedge funds
104.95K
-1.25M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 0 | 10836 |
| May 2024 | 0 | 20315 |
| Jun 2024 | 0 | 43593 |
| Dec 2024 | 400 | 0 |
| Patent |
|---|
Application Filling date: 23 Jul 2021 Issue date: 20 Jan 2022 |
Application Filling date: 22 Jan 2021 Issue date: 6 Jan 2022 |
Application Filling date: 28 May 2021 Issue date: 25 Nov 2021 |
Application Filling date: 6 Nov 2020 Issue date: 30 Sep 2021 |
Grant Utility: Peptidomimetic macrocycles Filling date: 6 Sep 2019 Issue date: 18 May 2021 |
Grant Utility: Peptidomimetic macrocycles Filling date: 18 Dec 2018 Issue date: 6 Apr 2021 |
Grant Filling date: 24 Sep 2015 Issue date: 2 Feb 2021 |
Application Filling date: 22 May 2020 Issue date: 26 Nov 2020 |
Application Filling date: 13 Mar 2020 Issue date: 17 Sep 2020 |
Grant Utility: Peptidomimetic macrocycles Filling date: 10 Sep 2018 Issue date: 7 Jul 2020 |
| Quarter | Transcript |
|---|---|
| Q3 2019 10 Nov 2019 | Q3 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Manuel C. Aivado (1970) Pres, Chief Executive Officer & Director | $1,060,000 |
Dr. Vojislav Vukovic M.D., Ph.D. (1967) Senior Vice President & Chief Medical Officer | $676,440 |
Mr. Richard J. Wanstall M.B.A. (1969) SVice President, Chief Financial Officer & Treasurer | $551,690 |
-
When is Aileron Therapeutics's next earnings date?
Unfortunately, Aileron Therapeutics's (ALRN) next earnings date is currently unknown.
-
Does Aileron Therapeutics pay dividends?
No, Aileron Therapeutics does not pay dividends.
-
How much money does Aileron Therapeutics make?
Aileron Therapeutics has a market capitalization of 37.98M. Aileron Therapeutics made a loss 15.73M US dollars in net income (profit) last year or -$1.02 on an earnings per share basis.
-
What is Aileron Therapeutics's stock symbol?
Aileron Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ALRN".
-
What is Aileron Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aileron Therapeutics?
Shares of Aileron Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aileron Therapeutics's key executives?
Aileron Therapeutics's management team includes the following people:
- Dr. Manuel C. Aivado Pres, Chief Executive Officer & Director(age: 55, pay: $1,060,000)
- Dr. Vojislav Vukovic M.D., Ph.D. Senior Vice President & Chief Medical Officer(age: 58, pay: $676,440)
- Mr. Richard J. Wanstall M.B.A. SVice President, Chief Financial Officer & Treasurer(age: 56, pay: $551,690)
-
How many employees does Aileron Therapeutics have?
As Jul 2024, Aileron Therapeutics employs 15 workers, which is 150% more then previous quarter.
-
When Aileron Therapeutics went public?
Aileron Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 29 Jun 2017.
-
What is Aileron Therapeutics's official website?
The official website for Aileron Therapeutics is aileronrx.com.
-
Where are Aileron Therapeutics's headquarters?
Aileron Therapeutics is headquartered at 285 Summer Street, Boston, MA.
-
How can i contact Aileron Therapeutics?
Aileron Therapeutics's mailing address is 285 Summer Street, Boston, MA and company can be reached via phone at +61 79950900.
Aileron Therapeutics company profile:
Aileron Therapeutics, Inc.
aileronrx.comExchange:
NASDAQ
Full time employees:
15
Industry:
Biotechnology
Sector:
Healthcare
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
285 Summer Street
Boston, MA 02210
Boston, MA 02210
CIK: 0001420565
ISIN: US00887A2042
CUSIP: 00887A105
